The deal brings to six the number of academic institutions from which Fate has licensed IP related to using small molecules to induce pluripotency in stem cells for therapeutic effect, drug discovery, and matched cell-replacement therapies.
If MedImmune can develop and market a drug based on the discovery, it could be a financial boost to the institute, which hopes to diversify its revenue sources once cash from sole corporate sponsor Kirin Pharma USA dries up in 2010.
At the public meeting, speakers from groups representing employers and employees pointed out the need for the EEOC to clarify "inadvertent acquisition" of genetic information under which employers would not be held in violation of the law and to provide specific examples of the types of genetic information linked to "manifested diseases" which the law does not protect.
The data presented last week at the Molecular Medicine Tri-Conference showed that the investigational test detected "dramatically different" miRNA expression patterns in the blood of cancer patients compared to those who were cancer-free.
Using gene expression and copy number analyses of dozens of endometrial cancers, an international research team has turned up characteristic expression profiles and gene amplifications linked to poor outcomes.
Both the project and the service are designed to offer cancer patients detailed information about their tumor at a timescale that can help their physicians tailor treatments. However, some experts say the results will not benefit many patients today.
The firm will use the undisclosed amount to optimize the protocols for its genomic-selection application and to start building a sales and marketing force that "will become more visible in the second half of this year," CEO Fred Dom said.
The public-private BioBusiness Alliance of Minnesota said the state should develop clusters in animal health, food, biofuel/renewable energy, and renewable materials capable of competing with other states.
Speakers at the Future of Genomic Medicine conference tempered their enthusiasm about the field by highlighting a number of obstacles standing in the way of making whole-genome studies a standard part of medical care.